Comparison of Testing Methods for the Detection of BRAF V600E Mutations in Malignant Melanoma: Pre-Approval Validation Study of the Companion Diagnostic Test for Vemurafenib

Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma

(2012) Harkanwal Halait et al.   DIAGNOSTIC MOLECULAR PATHOLOGY

BRAFmutation testing in clinical practice

(2012) James Ziai et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Co-development of a companion diagnostic for targeted cancer therapy

(2012) Suzanne Cheng et al.   New Biotechnology

Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma

(2012) Molly Yancovitz et al.   PLoS One

Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma

(2011) J. J. Luke et al.   CLINICAL CANCER RESEARCH

Cancer drugs find a companion with new diagnostic tests

(2011) Charlotte Schubert   NATURE MEDICINE

Predictive biomarkers: a paradigm shift towards personalized cancer medicine

(2011) Nicholas B. La Thangue et al.   Nature Reviews Clinical Oncology

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

(2010) H. Yang et al.   CANCER RESEARCH

A Commercial Real-Time PCR Kit Provides Greater Sensitivity than Direct Sequencing to Detect KRAS Mutations

(2010) Bárbara Angulo et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

(2010) Jill C Rubinstein et al.   Journal of Translational Medicine